AR and prostate carcinoma: As a second-generation AR antagonist, enzalutamide has been widely used in treatment of advanced prostate cancer although the development of resistance is inevitable.35 In this study, we showed that EMT plays an important role in the development of enzalutamide resistance and metformin is capable of reversing enzalutamide-induced EMT.